Home
HelpTest Code EDN Eosinophil Derived Neurotoxin, Serum
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Within 12 hours of collection, centrifuge and aliquot serum into a plastic vial. Serum cannot sit on either gel or cells for longer than 12 hours.
Useful For
Evaluating patients suspected to have a condition associated with eosinophilia or hypereosinophilia
Evaluating patients with elevated peripheral blood eosinophil counts
Managing patients with elevated eosinophil-derived neurotoxin in the context of eosinophil-associated diseases
Method Name
Fluorescence Enzyme Immunoassay (FEIA)
Reporting Name
Eosinophil Derived Neurotoxin, SSpecimen Type
SerumSpecimen Minimum Volume
0.3 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 7 days |
| Frozen | 21 days |
Reference Values
<70 mcg/L: Normal
70-99 mcg/L: Borderline
≥100 mcg/L: Elevated
Reference values apply to all ages.
Interpretation
Eosinophil-derived neurotoxin (EDN) concentrations greater than or equal to 100 mcg/L, in the presence of elevated numbers of peripheral blood or tissue-resident eosinophils, may be suggestive of inflammation or increased disease activity in patients with eosinophil-associated diseases.
In the context of normal eosinophil counts, EDN concentrations greater than 70 mcg/L may indicate cellular activation and degranulation.
In the context of elevated eosinophil counts, EDN concentrations less than or equal to 70 mcg/L may indicate limited or absent cellular activation.
Clinical Reference
1. Wechsler ME, Munitz A, Ackerman SJ, et al. Eosinophils in health and disease: A state-of-the-art review. Mayo Clin Proc. 2021;96(10):2694-2707
2. Mattis DM, Wang SA, Lu CM. Contemporary classification and diagnostic evaluation of hypereosinophilia. Am J Clin Pathol. 2020;154(3):305-318
3. Shomali W, Gotlib J. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99(5):946-968
4. Rutten B, Young S, Rhedin M, et al. Eosinophil-derived neurotoxin: A biologically and analytically attractive asthma biomarker. PLoS ONE. 2021;16(2):e0246627
5. Rydell N, Nagao M, Ekoff H, et al. Development of an automated ImmunoCAP research assay for eosinophil derived neurotoxin and its use in asthma diagnosis in children. Pract Lab Med. 2019;17:300138
Day(s) Performed
Tuesday
Report Available
2 to 8 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
83520
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| EDN | Eosinophil Derived Neurotoxin, S | 100976-0 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| EDN | Eosinophil Derived Neurotoxin, S | 100976-0 |